IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v470y2011i7332d10.1038_nature09671.html
   My bibliography  Save this article

Oncogenically active MYD88 mutations in human lymphoma

Author

Listed:
  • Vu N. Ngo

    (Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Present address: Division of Hematopoietic Stem Cell and Leukemia Research, City of Hope National Medical Center, Duarte, California 91010, USA.)

  • Ryan M. Young

    (Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA)

  • Roland Schmitz

    (Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA)

  • Sameer Jhavar

    (Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA)

  • Wenming Xiao

    (Bioinformatics and Molecular Analysis Section, Center for Information Technology, National Institutes of Health)

  • Kian-Huat Lim

    (Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA)

  • Holger Kohlhammer

    (Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA)

  • Weihong Xu

    (Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA)

  • Yandan Yang

    (Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA)

  • Hong Zhao

    (Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA)

  • Arthur L. Shaffer

    (Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA)

  • Paul Romesser

    (Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Howard Hughes Medical Institute-National Institutes of Health Research Scholars Program)

  • George Wright

    (Biometric Research Branch, DCTD, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA)

  • John Powell

    (Bioinformatics and Molecular Analysis Section, Center for Information Technology, National Institutes of Health)

  • Andreas Rosenwald

    (University of Würzburg, 97080 Würzburg, Germany)

  • Hans Konrad Muller-Hermelink

    (University of Würzburg, 97080 Würzburg, Germany)

  • German Ott

    (Robert-Bosch-Krankenhaus, and Dr Margarete Fischer-Bosch Institute for Clinical Pharmacology, 70376 Stuttgart, Germany)

  • Randy D. Gascoyne

    (British Columbia Cancer Agency, Vancouver, British Columbia V5Z 4E6, Canada)

  • Joseph M. Connors

    (British Columbia Cancer Agency, Vancouver, British Columbia V5Z 4E6, Canada)

  • Lisa M. Rimsza

    (University of Arizona
    Southwest Oncology Group, 24 Frank Lloyd Wright Drive)

  • Elias Campo

    (Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain)

  • Elaine S. Jaffe

    (Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA)

  • Jan Delabie

    (Pathology Clinic, Rikshospitalet University Hospital, N-0310 Oslo, Norway)

  • Erlend B. Smeland

    (Institute for Cancer Research, Rikshospitalet University Hospital and Center for Cancer Biomedicine, University of Oslo, N-0310 Oslo, Norway)

  • Richard I. Fisher

    (Southwest Oncology Group, 24 Frank Lloyd Wright Drive
    James P. Wilmot Cancer Center, University of Rochester School of Medicine)

  • Rita M. Braziel

    (Southwest Oncology Group, 24 Frank Lloyd Wright Drive
    Oregon Health and Science University)

  • Raymond R. Tubbs

    (Southwest Oncology Group, 24 Frank Lloyd Wright Drive
    Cleveland Clinic Pathology and Laboratory Medicine Institute)

  • J. R. Cook

    (Southwest Oncology Group, 24 Frank Lloyd Wright Drive
    Cleveland Clinic Pathology and Laboratory Medicine Institute)

  • Denny D. Weisenburger

    (University of Nebraska Medical Center)

  • Wing C. Chan

    (University of Nebraska Medical Center)

  • Louis M. Staudt

    (Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA)

Abstract

MYD88 signalling in cancer RNA interference screening and high-throughput RNA resequencing have been used to reveal oncogenic mutations in the signalling adapter MYD88 in human lymphomas. One amino acid substitution, L265P, was found in 29% of biopsies from patients with the activated B-cell-like subtype of diffuse large B-cell lymphoma. The same mutation was observed with lower frequency in mucosa-associated lymphoid tissue lymphomas. MYD88 mediates signalling by Toll-like receptors, and the mutations, most of which affect the same amino acid, were shown to activate the pathway and promote cancer cell survival.

Suggested Citation

  • Vu N. Ngo & Ryan M. Young & Roland Schmitz & Sameer Jhavar & Wenming Xiao & Kian-Huat Lim & Holger Kohlhammer & Weihong Xu & Yandan Yang & Hong Zhao & Arthur L. Shaffer & Paul Romesser & George Wright, 2011. "Oncogenically active MYD88 mutations in human lymphoma," Nature, Nature, vol. 470(7332), pages 115-119, February.
    • Handle: RePEc:nat:nature:v:470:y:2011:i:7332:d:10.1038_nature09671
    DOI: 10.1038/nature09671
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature09671
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature09671?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Josefine Radke & Naveed Ishaque & Randi Koll & Zuguang Gu & Elisa Schumann & Lina Sieverling & Sebastian Uhrig & Daniel Hübschmann & Umut H. Toprak & Cristina López & Xavier Pastor Hostench & Simone B, 2022. "The genomic and transcriptional landscape of primary central nervous system lymphoma," Nature Communications, Nature, vol. 13(1), pages 1-20, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:470:y:2011:i:7332:d:10.1038_nature09671. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.